Adagio Medical expands board to seven, appoints former Medtronic EVP Sean Salmon

Adagio Medical Holdings, Inc.

Board increased from six to seven directors; Salmon appointed Class II director, term expiring at 2026 annual meeting.
Salmon served as Medtronic EVP and President of Cardiovascular Portfolio from Jan 2021 to Sep 2025.
Appointed to Audit and Compensation Committees; will receive standard non-employee director compensation.
Company entered into standard indemnification agreement with Salmon.
No arrangements or material transactions with any other person in connection with appointment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.